Back to Search Start Over

Design and Rationale for a Real-World Prospective, Multicenter Registry of Myocardial Revascularization Failure and Secondary Revascularization: The REVASEC Study

Authors :
José Antonio Fernández-Díaz
Tamara Garcia-Camarero
Ander Regueiro
Antonio Gómez-Menchero
Ignacio J. Amat-Santos
Carlos Macaya
Antonio Serra
Marcelo Jimenez-Kockar
Sergio García-Blas
José Luis Poveda-Andrés
Virginia Pascual Tejerina
Ignacio Cruz-González
Antonio Castro
Juan Rondan
Jose Luis Diez-Gil
Javier Escaned
José Francisco Díaz-Fernández
Eduardo Flores-Umanzor
Sandra Rosillo
Jean Paul Vilchez-Tschischke
Soledad Ojeda
Jessika González-D'Gregorio
Beatriz de Tapia
Javier García Perez-Velasco
Pablo Salinas
José M. de la Torre-Hernández
Fernando Macaya
Fernando Lozano Ruiz-Poveda
Francisco J. Noriega
María del Carmen Manzano
Source :
Cardiovascular revascularization medicine : including molecular interventions, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, Consejo Superior de Investigaciones Científicas (CSIC), r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
Publication Year :
2021

Abstract

AIM: To investigate key aspects of the problem of myocardial revascularization failure (MRF) and repeat or secondary myocardial revascularization (SR) in contemporary practice.; METHODS: The registry of secondary revascularization (REVASEC) is an investigator-initiated, multicenter, prospective registry enhanced with data monitoring and independent event adjudication (ClinicalTrials.govNCT03349385). It includes patients with prior revascularization referred to coronary angiography for suspected MRF with broad inclusion criteria. The main objectives are to describe the characteristics of patients with prior revascularization referred for repeat angiography, to describe and the rate and mechanisms of MRF (stent or graft failure, coronary artery disease progression or residual coronary artery disease); to evaluate the management including medical treatment and SR of these patients; and to assess the prognosis according to the outlined causative mechanisms. The registry has one year follow up for the primary endpoint (Patient-oriented composite endpoint including all-cause death, any myocardial infarction or any new unplanned revascularization according to subsets of MRF), but extended follow-up will be carried out up to 5years.; CONCLUSION: The REVASEC Registry will provide updated data on the characteristics, patterns of treatment, and 1-year outcomes of patients with MRF and SR in contemporary clinical practice. Copyright © 2021. Published by Elsevier Inc.

Details

ISSN :
18780938 and 15538389
Volume :
40
Database :
OpenAIRE
Journal :
Cardiovascular revascularization medicine : including molecular interventions
Accession number :
edsair.doi.dedup.....f897e819da5c91f7749d64bdfa6b6a89